PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade - PubMed (original) (raw)
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade
Maisa Yoshimoto et al. Mod Pathol. 2013 Mar.
Free article
Abstract
Prostatic adenocarcinoma is an epithelial malignancy characterized by marked histological heterogeneity. It most often has a multifocal distribution within the gland, and different Gleason grades may be present within different foci. Data from our group and others have shown that the genomic deletion of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor gene and the disruption of the ETS gene family have a central role in prostate cancer and are likely to be associated with Gleason grade. In this study, prostate cancer samples were systematically analyzed to determine whether there was concordance between PTEN losses and TMPRSS2-ERG fusion rearrangements, within or between foci in multifocal disease, using well-annotated tissue microarrays (TMAs) consisting of 724 cores derived from 142 radical prostatectomy specimens. Three-color fluorescence in situ hybridization analysis of both the PTEN deletion and the TMPRSS2-ERG fusion was used to precisely map genetic heterogeneity, both within and between tumor foci represented on the TMA. PTEN deletion was observed in 56 of 134 (42%) patients (hemizygous=42 and homozygous=14). TMPRSS2-ERG fusion was observed in 63 of 139 (45%) patients. When analyzed by Gleason pattern for a given TMA core, PTEN deletions were significantly associated with Gleason grades 4 or 5 over grade 3 (P<0.001). Although TMPRSS2-ERG fusions showed a strong relationship with PTEN deletions (P=0.007), TMPRSS2-ERG fusions did not show correlation with Gleason grade. The pattern of genetic heterogeneity of PTEN deletion was more diverse than that observed for TMPRSS2-ERG fusions in multifocal disease. However, the marked interfocal discordance for both TMPRSS2-ERG fusions and PTEN deletions was consistent with the concept that multiple foci of prostate cancer arise independently within the same prostate, and that individual tumor foci can have distinct patterns of genetic rearrangements.
Similar articles
- Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA. Yoshimoto M, et al. Mod Pathol. 2008 Dec;21(12):1451-60. doi: 10.1038/modpathol.2008.96. Epub 2008 May 23. Mod Pathol. 2008. PMID: 18500259 - Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Murphy SJ, Karnes RJ, Kosari F, Castellar BE, Kipp BR, Johnson SH, Terra S, Harris FR, Halling GC, Klein JL, Nasir A, Bergstrahl E, Rangel LJ, Sukov WR, Vasmatzis G, Cheville JC. Murphy SJ, et al. Mod Pathol. 2016 Feb;29(2):143-56. doi: 10.1038/modpathol.2015.136. Epub 2015 Nov 27. Mod Pathol. 2016. PMID: 26612463 - Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L, Stahl P, C Tsourlakis M, Bauer M, Tennstedt P, Graefen M, Steurer S, Sirma H, Sauter G, Schlomm T, Simon R, Minner S. Krohn A, et al. Mod Pathol. 2014 Dec;27(12):1612-20. doi: 10.1038/modpathol.2014.70. Epub 2014 Apr 25. Mod Pathol. 2014. PMID: 24762546 - TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.
Zhou CK, Young D, Yeboah ED, Coburn SB, Tettey Y, Biritwum RB, Adjei AA, Tay E, Niwa S, Truelove A, Welsh J, Mensah JE, Hoover RN, Sesterhenn IA, Hsing AW, Srivastava S, Cook MB. Zhou CK, et al. Am J Epidemiol. 2017 Dec 15;186(12):1352-1361. doi: 10.1093/aje/kwx235. Am J Epidemiol. 2017. PMID: 28633309 Free PMC article. Review.
Cited by
- Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.
Segalés L, Juanpere N, Lorenzo M, Albero-González R, Fumadó L, Cecchini L, Bellmunt J, Lloreta-Trull J, Hernández-Llodrà S. Segalés L, et al. Virchows Arch. 2019 Oct;475(4):457-466. doi: 10.1007/s00428-019-02573-1. Epub 2019 Apr 23. Virchows Arch. 2019. PMID: 31016435 - Correlations of PTEN and ERG Immunoexpression in Prostate Carcinoma and Lesions Related to Its Natural History: Clinical Perspectives.
Voulgari O, Goutas D, Pergaris A, Belogiannis K, Thymara E, Kavantzas N, Lazaris AC. Voulgari O, et al. Curr Issues Mol Biol. 2023 Mar 25;45(4):2767-2780. doi: 10.3390/cimb45040181. Curr Issues Mol Biol. 2023. PMID: 37185705 Free PMC article. - SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC, Evans A, Donnelly B, Bismar TA. Huang KC, et al. Pathol Oncol Res. 2017 Apr;23(2):399-407. doi: 10.1007/s12253-016-0119-9. Epub 2016 Oct 13. Pathol Oncol Res. 2017. PMID: 27738792 - Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, Spratt DE, Palapattu GS, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA. Mehra R, et al. Med Oncol. 2018 Oct 5;35(12):152. doi: 10.1007/s12032-018-1212-6. Med Oncol. 2018. PMID: 30291535 Free PMC article. - Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.
Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM. Hong MK, et al. Nat Commun. 2015 Apr 1;6:6605. doi: 10.1038/ncomms7605. Nat Commun. 2015. PMID: 25827447 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials